share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4:持股變動聲明-高管 Colvin Richard A
美股SEC公告 ·  10/02 16:12

Moomoo AI 已提取核心訊息

On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
2024年9月30日,bluebird bio公司的首席醫療官Richard A Colvin完成了一項交易,免費獲得了該公司的50000股普通股。這份股票贈與使得Colvin在該公司的直接持股總數增加到了168368股。這項交易並非在公開市場購買,而是一次贈與,體現了公司對其高管的補償或激勵策略。這些股份直接贈予Colvin,凸顯了他對公司表現的利益關係。
2024年9月30日,bluebird bio公司的首席醫療官Richard A Colvin完成了一項交易,免費獲得了該公司的50000股普通股。這份股票贈與使得Colvin在該公司的直接持股總數增加到了168368股。這項交易並非在公開市場購買,而是一次贈與,體現了公司對其高管的補償或激勵策略。這些股份直接贈予Colvin,凸顯了他對公司表現的利益關係。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息